Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
Abstract Background Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive tumor with a poor prognosis and standard therapy has not yet been established. Case A 65‐year‐old male with a cough for 2 months presented to our hospital. He was clinically diagnosed with non small ce...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1589 |
| _version_ | 1818491213630668800 |
|---|---|
| author | Naoki Kadota Nobuo Hatakeyama Hiroyuki Hino Michihiro Kunishige Yoshihiro Kondo Yoshio Okano Hisanori Machida Keishi Naruse Tsutomu Shinohara Shoji Sakiyama Fumitaka Ogushi Eiji Takeuchi |
| author_facet | Naoki Kadota Nobuo Hatakeyama Hiroyuki Hino Michihiro Kunishige Yoshihiro Kondo Yoshio Okano Hisanori Machida Keishi Naruse Tsutomu Shinohara Shoji Sakiyama Fumitaka Ogushi Eiji Takeuchi |
| author_sort | Naoki Kadota |
| collection | DOAJ |
| description | Abstract Background Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive tumor with a poor prognosis and standard therapy has not yet been established. Case A 65‐year‐old male with a cough for 2 months presented to our hospital. He was clinically diagnosed with non small cell lung cancer cT3N1M0 stage IIIA and underwent right pneumonectomy. The final diagnosis was pulmonary LCNEC pT3N1M0 stage IIIA. Multiple subcutaneous masses were detected 4 months after surgery, and biopsy revealed postoperative recurrence and metastasis. Chemotherapy with carboplatin plus etoposide was initiated. Subcutaneous masses increased and multiple new brain metastases developed after two cycles. Additional tests revealed that epidermal growth factor receptor and anaplastic lymphoma kinase were negative, and the programmed death ligand 1 (PD‐L1) expression rate in tumor cells was 40% (22C3 clones). The primary cells infiltrating the tumor were CD3‐positive T cells and CD138‐positive plasma cells. Second‐line treatment with pembrolizumab was started. The shrinkage of subcutaneous masses was observed after one cycle, and the tumor had completely disappeared after six cycles. Treatment was continued for approximately 2 years. This response has been maintained for 4 years and is still ongoing. Conclusion Pembrolizumab may be used as a treatment option for pulmonary LCNEC. |
| first_indexed | 2024-12-10T17:27:38Z |
| format | Article |
| id | doaj.art-6ff497dc406e4cfeb3c728ca40941aa2 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-12-10T17:27:38Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-6ff497dc406e4cfeb3c728ca40941aa22022-12-22T01:39:48ZengWileyCancer Reports2573-83482022-08-0158n/an/a10.1002/cnr2.1589Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumabNaoki Kadota0Nobuo Hatakeyama1Hiroyuki Hino2Michihiro Kunishige3Yoshihiro Kondo4Yoshio Okano5Hisanori Machida6Keishi Naruse7Tsutomu Shinohara8Shoji Sakiyama9Fumitaka Ogushi10Eiji Takeuchi11Department of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi JapanDepartment of Thoracic Surgery National Hospital Organization Kochi Hospital Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi JapanDepartment of Pathology National Hospital Organization Kochi Hospital Kochi JapanDepartment of Community Medicine for Respirology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Thoracic Surgery National Hospital Organization Kochi Hospital Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi JapanDepartment of Clinical Investigation National Hospital Organization Kochi Hospital Kochi JapanAbstract Background Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive tumor with a poor prognosis and standard therapy has not yet been established. Case A 65‐year‐old male with a cough for 2 months presented to our hospital. He was clinically diagnosed with non small cell lung cancer cT3N1M0 stage IIIA and underwent right pneumonectomy. The final diagnosis was pulmonary LCNEC pT3N1M0 stage IIIA. Multiple subcutaneous masses were detected 4 months after surgery, and biopsy revealed postoperative recurrence and metastasis. Chemotherapy with carboplatin plus etoposide was initiated. Subcutaneous masses increased and multiple new brain metastases developed after two cycles. Additional tests revealed that epidermal growth factor receptor and anaplastic lymphoma kinase were negative, and the programmed death ligand 1 (PD‐L1) expression rate in tumor cells was 40% (22C3 clones). The primary cells infiltrating the tumor were CD3‐positive T cells and CD138‐positive plasma cells. Second‐line treatment with pembrolizumab was started. The shrinkage of subcutaneous masses was observed after one cycle, and the tumor had completely disappeared after six cycles. Treatment was continued for approximately 2 years. This response has been maintained for 4 years and is still ongoing. Conclusion Pembrolizumab may be used as a treatment option for pulmonary LCNEC.https://doi.org/10.1002/cnr2.1589complete responseimmune checkpoint inhibitorpembrolizumabplasma cellpulmonary large cell neuroendocrine carcinoma |
| spellingShingle | Naoki Kadota Nobuo Hatakeyama Hiroyuki Hino Michihiro Kunishige Yoshihiro Kondo Yoshio Okano Hisanori Machida Keishi Naruse Tsutomu Shinohara Shoji Sakiyama Fumitaka Ogushi Eiji Takeuchi Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab Cancer Reports complete response immune checkpoint inhibitor pembrolizumab plasma cell pulmonary large cell neuroendocrine carcinoma |
| title | Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab |
| title_full | Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab |
| title_fullStr | Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab |
| title_full_unstemmed | Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab |
| title_short | Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab |
| title_sort | complete and durable response of pulmonary large cell neuroendocrine carcinoma to pembrolizumab |
| topic | complete response immune checkpoint inhibitor pembrolizumab plasma cell pulmonary large cell neuroendocrine carcinoma |
| url | https://doi.org/10.1002/cnr2.1589 |
| work_keys_str_mv | AT naokikadota completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT nobuohatakeyama completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT hiroyukihino completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT michihirokunishige completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT yoshihirokondo completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT yoshiookano completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT hisanorimachida completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT keishinaruse completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT tsutomushinohara completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT shojisakiyama completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT fumitakaogushi completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab AT eijitakeuchi completeanddurableresponseofpulmonarylargecellneuroendocrinecarcinomatopembrolizumab |